Greg B. Scott – President and Founder, ChinaBio® LLC
Greg Scott has helped launch over thirty life science startups in the U.S. and China as a founder, investor and advisor. He founded ChinaBio® Accelerator to help fund and mentor early stage life science companies in China. He is also the Founding Principal of ChinaBio® Consulting which assists U.S. and China life science companies and investors leverage the opportunities available in China. Mr. Scott is also the president and co-founder of Life Science Angels, an angel investment group that has funded 30 biotechnology and medical device companies since 2005, and executive editor of the ChinaBio® Today newsletter. He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and founded and sold three high-tech firms. Mr. Scott attended University of Missouri, where he studied mathematics, microbiology and computer science.
Charles Hsu, PhD, MBA - Venture Partner, Bay City Capital
Dr. Hsu has over 20 years of life science industry experience, including 17 years as an entrepreneur and venture capitalist, dedicated to investments in early-stage life science and healthcare companies. He was a General Partner of the Walden Group and its affiliate Walden International from early 1996 through mid-2003. Prior to joining Walden, he co-managed life science investments at Advent International, a global private equity firm, based in Boston. He has co-founded or invested in over 25 companies, and has served as a Director on over 15 Boards. He has been investing internationally throughout his career, and has been involved with several companies in the Greater China region, as founder, investor, director and/or advisor, including Asia Renal Care, Wuxi Pharmatech, Eureka, Progentech and LEAD Therapeutics. He holds an AB in Biochemistry from Harvard and his PhD and MBA from Stanford
Yuwen Liu, MBA - General Manager, Suzhou/BioBay
Liu Yuwen graduated from China Pharmaceutical University with an Ms in Pharmaceutics and MBA at Fudan University, China and Norwegian Management School, and is a licensed pharmacist. She started her career with Capsugel® , a division of Pfizer in Suzhou, China as a quality engineer in 1997 and was promoted to be QA manager in April 1998. In May 2000, following strategic expansion of Capsugel China, she transferred to New Business Development department managing new product market opportunity exploration in great China region. In May 2003, she moved to Shanghai as General Manager to set up the representative office for Perrigo Company (the world’s largest manufacturer of OTC pharmaceutical and nutritional products for the store brand market) and is taking charge of all related market development activities including JV’s in China as well as supply management in other Asia Pacific regions such as Japan, Korea, Taiwan etc. In Dec. 2005, she moved back to Suzhou as executive vice president for BioBay, a bio science park funded by Suzhou Industrial Park, whose mission is to build an integrated comprehensive platform for biotech, pharmaceutical and nanotech research and development in China. August, 2007, she became the general manager of BioBay, vice president of Suzhou Ventures Group, assistance director of Suzhou Industrial Park Science & Technology Bureau.
Wen Chen, MBA, VP - Business Development, Tigermed Consulting Ltd.
Mr. Wen Chen joined Tigermed as Vice President of Business Development in May, 2009. Before this appointment, he oversaw operation and business development at HD Biosciences, a Shanghai-based preclinical CRO. In 2008, he led the effort to raise Series A financing for HDB from Pfizer, Lilly Asia Venture and Morningside Technology. From 2005 to 2007, Wen was chief representative then executive VP of China operation for Huya Biosciences International, a San Diego biotech company dedicating to license proprietary NCE originated from China for global product development. He was instrumental in sourcing, negotiation the licensing and transferring 2 proprietary Chinese NCEs to the States for FDA IND filings. Wen also worked for Shanghai Huayi Bio-lab in product development and IgCon Therapeutics in Shanghai as well as a TCM portfolio company of Hong Kong New World China Enterprise between 2000 to 2005. Mr. Chen received his undergraduate degree in biochemistry from Purdue University in Indiana and graduate training in immunology and oncology at Washington University School of Medicine and Harvard University Beth Israel Medical Center. He then worked at Amgen in Thousand Oaks. He received his MBA from Durham University in UK.
Charles C. Comey, JD - Managing Partner, Morrison & Foerster
Charles Comey is Managing Partner of Morrison & Foerster’s Shanghai office and co-chair of the China Private Equity Group. He advises clients on a wide variety of private equity, mergers and acquisitions as well as other corporate finance, joint venture, life sciences, and technology matters. Mr. Comey is recognized by Chambers Global 2009, IFLR 1000, and PLC Cross-border Which Lawyer? for his expertise in private equity and venture investments in China and Asia. Mr. Comey earned his B.A. from Yale University, M.A. from the University of California, Berkeley, and J.D. from the University of California, Los Angeles. Prior to practicing in Shanghai, Mr. Comey worked in Tokyo and Silicon Valley. He speaks and reads Mandarin
Alex Fowkes, JD – Executive Director and Head of R&D Business Development, Asia, Pfizer (China)
Alex Fowkes obtained undergraduate degrees in science and law in Australia before joining a private practice law firm in 1994. In 1998 Alex joined Pfizer’s operations in the United Kingdom to provide legal support to its European research and development activities. In 2003 Alex moved to the Pfizer Research and Development Division (PGRD) headquarters in New London, Connecticut to lead the global legal support for PGRD’s world-wide technology transfer activities. At the end of 2006 Alex was appointed to lead PGRD’s Strategic Alliance operations in Asia and relocated to Pfizer’s Research Office in Shanghai.
Jennifer Hu, PhD – Director of Licensing & External Research, Merck & Co., USA
Dr. Jing-Shan Hu is currently Director of Licensing & External Research (Mainland China, Hong Kong, & Taiwan) at Merck & Co., Inc., USA. She is responsible for identifying and developing opportunities related to partnership, licensing-in, and acquisition for new drug candidates and technologies for drug discovery and development in Mainland China, Hong Kong, and Taiwan. Prior to joining Merck & Co., Inc., Dr. Hu spent over three years with Roche Pharmaceuticals at Palo Alto as Research Leader and Head of Functional Biology following serving as the Program Leader for Toxicogenomics. Prior to that, she worked at Affymetrix in various capacities, including as Program Manager of Toxicology/Pharmacogenomics, establishing and managing programs with both pharmaceutical and academic partners to develop and demonstrate the application of Affymetrix GeneChip technology. She started her career at Human Genome Sciences as one of the founding scientists and Project Leader of VEGF-2 Protein Therapeutics program. Dr. Hu got her B.S. degree in Biochemistry from Peking University; Ph.D. from Univ. of Texas & M.D. Anderson Cancer Center through CUSBEA program; her post-doctoral training at Harvard Medical School. She has authored 15 papers in peer reviewed journals such as Science, Nature Genetics, and Nature. She is also an inventor of 16 patents and patent applications. She has served as the 2006-2007 President of Sino-American Pharmaceutical Professionals Association – West (SAPA-West) and the 2002-2003 Chairperson of the Board of Peking University Alumni Association of Northern California (PKUAANC). Dr. Hu has 16 years of research, management, & business development experience in biotech and pharmaceutical industry in the US.
Kewen Jin, PhD - General Manager, Charles River Greater China
Kewen Jin is currently General Manager of Charles River Laboratories (CRL) China preclinical service company. He was founder/CEO of BioExplorer, a preclinical CRO which formed a JV with CRL in 2007. Kewen has co-founded and served as key executive (CEO, CBO, and founding partner) for three other companies in the R&D outsourcing, drug discovery, and consulting. He served as advisor to several MNC pharma and healthcare companies, major consulting and investment firms. Previously, he was a marketing and international operation executive with Wyeth, first five years in the U.S. , then two years in Beijing. He is a Senior Advisor to Shanghai Pudong Government. He was granted the 2005 Magnolia Award, which the Shanghai government grants to individuals making major contribution to the development of Shanghai. He is a member of the Board of Directors for Bayhelix and Sino American Pharmaceutical Association (SAPA), two leading Chinese life science professional organizations. He was trained in medicine (Shanghai Jiaotong University School of Medicine), biology (Rockefeller), finance (Columbia).
Wayne Li, PhD - Moringside
Dr. Li joined Morningside in 2007. He has over 21 years of experience in biological and chemical sciences, of which over 12 years were dedicated to drug development. His expertise is in novel drug preclinical development. Dr. Li has held director and manager level positions at Genelabs, Rigel and Covance Laboratories. Dr. Li received his M.Sc. from the Chinese Academy of Sciences, and his PhD from Brigham Young University. He did post-doctoral research at the Haskell Laboratory for Toxicology and Industrial Medicine at DuPont where he subsequently worked as a research chemist.
William Li, MBA - Partner, Ginko Partners Ltd
William started his investment career as Project manager of China Singapore Suzhou Industrial Park Ventures(CSVC). William was Project Manager for Pacific Venture Partners, a Taiwan Based VC firm, for 16 months. After that, William became deputy GM for the investment department of CSVC. Three years later, William became a senior director for Infinity I-China Fund before he joined Ginko Partners, part of Suzhou Venture Group. William holds an MBA degree obtained from the Kennesaw State University and a BA in Economics, from the Shanghai Maritime University.
John Li - President and CEO, HOB Biotech Group
John LI graduated from Beijing University of Aeronautics and Astronautics, with a Bachelor degree in Rocket Science in 1984. He went to the USA for graduate study in 1989 and then worked there for a couple of years before returning to China. After his graduate study in managerial economics at the Ohio State University, he joined the world eye-care leader Alcon Lab in 1992 as the project manager. In 1995 he became the China Chief Representative for the Fortune 500 company Black & Decker. In 2000, John took the position of General Manager, Great China for Brady Corp. Brady, a NYSE listed company, is the world market leader in industrial identification. John managed Brady’s Greater China operation, including mainland China, Taiwan and Hong Kong. During his three and half years service at Brady, three factories were built, sales more than tripled and profit achieved ahead of plan. Now John is the president and CEO of HOB Biotech Group. HOB was founded by John without any outside financing. Today HOB Biotech is a well established manufacturer, product developer and marketer of immmunoassay IVD products. HOB is the market leader in allergy in-vitro diagnostics in China.
Maria Song, PhD, MD - President, VPS-CRO Group
Graduated from Peking Union Medical University in 1995, Dr Song was honored with M.D. Before joining Venturepharm Dr Song had been undertaking important positions in a famous pharmaceutical company. Leading R&D of a series of national type 1, type2 and type4 new drugs, Dr Song has enormous experience in the whole process of pre-clinical pharmacy, pharmacology and clinical research. From 2000 Dr Song has been directing at Venturepharm Laboratory, which is the first publicly listed and China based R&D pharmaceutical company. Venturepharm has been maintaining its leading position on pharmaceutical and R&D sector in China. Leading by Dr Song Venturepharm CRO Services has becoming the largest clinical CRO in China in terms of its therapeutic areas. Venturepharm CRO Services is the only international CRO in China, which is publicly listed abroad. It is also recognized as one of the most authority CRO in clinical research in traditional Chinese medicine. In year 2003, Venturepharm CRO Services is honored as one of the 10 best national foreign investor companies in China.
Jonathan Wang, PhD, MBA - Senior Managing Director, OrbiMed Asia
Dr. Jonathan Wang is a Senior Managing Director, at OrbiMed Asia. He is a general partner at OrbiMed’s Asia-focused VC fund. Previously, he was General Manager at Burrill Greater China Group and worked for WI Harper Group and Walden International, two pioneers in the Asia-related VC industry. At WI Harper, Dr. Wang was a Managing Director, overseeing the firm’s life sciences activities worldwide. There he co-founded and incubated Bridge Laboratories. Dr. Wang is a Board Director at ForteBio, Inc. He is also co-founder and former Chairman of The BayHelix Group, an organization of Chinese life sciences business leaders. He holds a Ph.D. in Molecular Neurobiology from Columbia University, where he obtained scientific training under the supervision of Dr. Eric Kandel, a Nobel Laureate. Dr. Wang also earned an M.B.A. from Stanford University.
Jimmy Wei, PhD, MBA - Vice Presient, Business Development, Hutchison MediPharma
Dr. Wei is currently Vice President and the head of the business development at Hutchison MediPharma (HMPL), one of the leading pharmaceutical R&D companies in China. Under his leadership, HMPL has established strategic partnerships with J&J, Eli Lilly, Merck Serono and other large global pharmaceutical companies. Previously, Dr. Wei was the Deputy General Manager of Burrill China Group, where he led Burrill & Company’s business activities related to Greater China Area. Prior to joining Burrill, Dr. Wei worked for WI Harper Group (WIH) and oversaw its global life sciences investment. Before WIH, Dr. Wei was a management consultant at McKinsey Shanghai office. Dr. Wei has also conducted R&D in several leading research organizations, including Duke University Medical Center and Chinese Academia of Sciences. Dr. Wei has obtained a Ph.D. in Biochemistry from North Carolina State University. He also holds an M.B.A. from Darden Business School, University of Virginia.
Timothy Wong, PhD - Market Development Manager, Drug Discovery, Pharma and CRO, Asia Pacific, Invitrogen, part of Life Technologies
Dr. Timothy Wong is the Asia Pacific Market Development Manager for Pharma and CRO sectors in Invitrogen, part of Life Technologies. He also holds business management responsibility in Invitrogen supporting drug discovery and development needs in Asia Pacific. He has been with Invitrogen and previously Life Technologies/GibcoBRL since 2000. Currently, apart from building Invitrogen’s drug discovery and development business in Asia Pacific, his role is to strategize partnership/collaboration model with pharmaceutical industry, CRO and research institutes to facilitate drug discovery research in Asia Pacific. Previously, he was responsible for Invitrogen technical services and marketing communication in Pacific regions while facilitating development of proteomic research in Asia by connecting Invitrogen resources to Human Proteomic Organization and the local scientific communities. Dr. Timothy Wong received his BSc (Hons) in Biology at The Hong Kong University of Sciences & Technologies. Dr. Wong received his Ph.D. in Biochemistry at Chinese University of Hong Kong with focus on identifying drug resistance mechanism and improving cancer drug efficacy in multidrug resistance cancer cells. Dr. Wong has received American Association for Cancer Research (AACR) Young Investigator Award.
Philip Xiao, MBA - Co-Founder and Chief Development Officer, Profex Inc.
Philip Xiao is Co-founder & CDO of Profex Inc. Profex Inc. is a leading dermatology company with largest Dermatology product portfolio and is currently ranked No. 2 in market share in China. Profex licenses, acquires, develops, and markets Dermatology & Cosmetic Dermatology related products for the China market. Before co-founding Profex, Philip was COO for eachnet.com. Prior to eachnet.com, Philip was the Vice President of Sales and Marketing and Board of Director for Bristol-Myers Squibb China where he led remarkable growth for the company. Philip is also a co-founder of NovaMed Pharmaceuticals, Inc. Philip is a native of Mainland China; he was trained as a Medical Doctor in China and received his MBA degree from Thunderbird.
Tao Xiong, JD, Partner, Broad & Bright
Tao Xiong is a Partner at the Shanghai office of Broad & Bright. Tao's practice focuses primarily on representing multinational companies in cross-border mergers and acquisitions, joint ventures, private equity and venture capital investment, and general corporate matters. Tao has extensive experience counseling clients in a variety of industries, including biotechnology, pharmaceutical, information technology, and consumer products. Prior to joining Broad & Bright, Tao was an associate at O’Melveny & Myers LLP and K&L Gates LLP, both major international law firms, where her practice focused on mergers & acquisitions, private equity, securities and general corporate counseling. Tao began her legal career in 1998 as a lecturer-in-law with Renmin University of China School of Law, a top law school in China, where she taught courses on international business law. Tao received her J.D. and LL.M., both from New York University School of Law. She also received her LL.M. and LL.B., both from Renmin University of China School of Law. Tao is admitted to the National Bar of China, the State Bar of New York, and the State Bar of Pennsylvania.
Michael Xu, MD, PhD - CEO, PegBio Co., Ltd.
Dr. Xu, whose expertise encompasses medicine, protein structure, pharmaceutical management, completed his M.D. degree from Hunan Medical University and PhD degree in Physiology and Biophysics from Columbia University at New York. Prior to founding PegBio, he was a GM of a joint venture pharmaceutical company in China for several years. Dr. Xu has published many scientific papers including in Science.
Stella Xu, PhD - Global Licensing Director, Roche Global Pharma Partnering
Dr. Stella Xu is the Global Licensing Director with Roche Global Pharma Partnering. Her major responsibilities include searching potential licensing opportunities (products / technologies), and supporting transaction discussions & alliance management with Asian partners. Prior to her current position, Stella had held multiple global positions in Roche Pharma Partnering and led more than 30 product-focused due diligence projects and alliances such as Toyama, Japan Tobacco, and Maxygen. Stella joined Roche from McKinsey & Company, a management consulting firm that provides strategic advices to the top management of global business leaders. At McKinsey, she led consulting engagements with biopharmaceutical clients in areas ranging from R&D strategy, marketing & sales, to corporate development and M&A activities. Prior to McKinsey, Stella was a research scientist with Isis Pharmaceuticals. Stella received her B.S. in Biophysics from Peking University; her Ph.D. in Biochemistry, Molecular Biology and Cell Biology from Northwestern University.
Yanning Yi, MBA - Vice President, The Balloch Group.
Yanning Yi joined The Balloch Group in 2007 and is focused on the firm's investment banking practices in healthcare sector. Mr. Yi has worked with the healthcare team of CIBC World Markets originating IPO transactions in US. He has extensive experience on private equity deals for CRO, specialty pharma, drug discovery, and medical device companies, including KPCB’s most recent $15 million investment in Genscript. Prior to joining TBG, Mr. Yi worked at CIBC in Toronto where he focused on credit and investment portfolio risk management. Prior to that, Mr. Yi spent seven years with China's largest policy bank, the China Development Bank, where he completed over $3 billion debt transactions in power, mining, manufacturing, and infrastructure industries. Mr. Yi received his MBA from the University of Western Ontario, Canada and his BA in Economics from the China Institute of Finance and Banking.
Peter Zhang, PhD - Chairman & CEO, Suzhou GenePharma Co., Ltd.
Dr. Peter Zhang graduated from Beijing University in 1988 and got his Ph.D. degree in Medicinal Chemistry. After that he worked for State Pharmaceutical Administration in Beijing for two years. In 1991 he joined Prof. C. B. Reese’s group in King’s College London to study nucleic acid chemistry. For more than five years in Prof. Reese’s lab, he was involved in developing new RNA chemistry, modification of nucleosides for antisense study, and methodology study in solution and solid phase DNA/RNA synthesis. In 1996, Dr. Zhang joined Cruachem Ltd. in Scotland, and started to work as Senior Nucleic Acid Chemist to develop new products, undertaking contract synthesis work. In 1998 he was promoted to the position of Specialty Chemicals Group Leader, taking the responsibility of directing new products development and specialty chemicals production. At the same time he was involved in technical support work, and in charge of sales work of South East Asia area. In 2003, he and other co-founders founded Shanghai GenePharma Co., Ltd. in China. The company is dedicated to develop RNA interference related new products and supply services to the RNAi research community.
John Zhu, PhD, MBA - Executive Director, Mingly China Growth Fund
John Zhu is the Executive Director of Mingly China Growth Fund. John has over 10 years of R&D and industry experience in the life science industry, including in product management, licensing and M&A. John received his PhD from University of Massachusetts Medical Center, and his MBA from University of California at Berkeley.